3.34
0.13 (4.02%)
| Penutupan Terdahulu | 3.21 |
| Buka | 3.34 |
| Jumlah Dagangan | 19,807 |
| Purata Dagangan (3B) | 22,243 |
| Modal Pasaran | 27,856,318 |
| Harga / Jualan (P/S) | 3.15 |
| Harga / Buku (P/B) | 8.66 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -431.34% |
| EPS Cair (TTM) | -12.00 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 67.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 837.11% |
| Nisbah Semasa (MRQ) | 2.01 |
| Aliran Tunai Operasi (OCF TTM) | -12.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.59 M |
| Pulangan Atas Aset (ROA TTM) | -37.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -206.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Evaxion A/S | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 23.07% |
| % Dimiliki oleh Institusi | 7.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merck & Co., Inc. | 30 Jun 2026 | 1,214,126 |
| Annis Gardner Whiting Capital Advisors, Llc | 30 Jun 2026 | 30,000 |
| J. Safra Sarasin Holding Ag | 30 Jun 2026 | 22,896 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |